23:36 , Apr 10, 2018 |  BC Extra  |  Preclinical News

Researchers identify coding, non-coding driver mutations in MM

Scientists from the Institute of Cancer Research (London, U.K.) identified coding and non-coding driver mutations involved in newly diagnosed multiple myeloma, suggesting the genes could be targeted to treat the disease. The research was published...
07:00 , Oct 3, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Interferon regulatory factor 4 (Irf4)-deficient mouse models of chronic lymphocytic leukemia (CLL) Irf4-deficient mice could be used to study...
07:00 , May 6, 2013 |  BioCentury  |  Strategy

Forma into the fold

Celgene Corp. has spent the last six years placing large bets on small biotechs doing breakthrough science and letting its partners take the wheel. Last week, the cancer and immunology company put its chips on...
07:00 , Aug 5, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Interferon regulatory factor 4 (IRF4); IL-9 In vitro and mouse studies suggest that IRF4 inhibition could...
07:00 , Jul 10, 2008 |  BC Innovations  |  Targets & Mechanisms

Myeloma's IRF4 Addiction

A paper published in Nature suggests that inhibiting interferon regulatory factor 4 could be useful for treating multiple myeloma (MM). Although the study identified the transcription factor as a regulator of several gene pathways central...
07:00 , Jul 10, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer ...